Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple SclerosisIzanne Roos, Vincent Van Pesch, Sifat Sharmin et al.|JAMA Neurology|2023Cited by 62
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple SclerosisJannis Müller, Tomáš Kalinčík, Masoud Etemadifar et al.|JAMA Neurology|2025Cited by 43
Predictors of treatment switching in the Big Multiple Sclerosis Data NetworkTim Spelman, Tobias Sejbæk, Koen de Gans et al.|Frontiers in Neurology|2023Cited by 9